Document:

<PAGE>

                                                                EXHIBIT 10.17(a)

                            FIRST AMENDMENT TO LEASE
                                    RENEWAL

This FIRST AMENDMENT TO LEASE (this "First Amendment") is made this 6th day of
December, 2005 by and between TEACHERS INSURANCE & ANNUITY ASSOCIATION OF
AMERICA, INC., a New York corporation ("Landlord") and HELIX BIOMEDIX, INC., a
Delaware corporation ("Tenant").

                                    RECITALS

     Landlord is the landlord and Tenant is the tenant under that certain Lease
dated August 14, 2001 (the "Initial Lease"), for premises located at 22122 20th
Avenue SE, Bothell, Washington, 98021, Building H, Unit 148 (the "Premises").
The Premises consists of 3,038 rentable square feet (being 2,378 rsf office and
660 rsf warehouse). As used herein the "Lease" shall mean the Initial Lease as
amended by this First Amendment.

     The parties desire to amend the Initial Lease to extend the Lease Term and
make certain other changes, on the following terms and conditions.

     Except as otherwise specifically defined herein all capitalized terms shall
have the meanings assigned in the Initial Lease.

                                    AGREEMENT

1. EXTENDED TERM OF THE LEASE. Section l(g) of the Initial Lease is hereby
amended to extend the Term of the Lease for a term ("Extended Term") commencing
on December 1, 2005 ("Extended Term Commencement Date") and terminating on
November 30, 2006 ("Expiration Date").

2. BASE MONTHLY RENT. From and after the Extended Term Commencement Date,
Section l(h) of the Initial Lease hereby is amended such that the Base Monthly
Rent during the Extended Term is as follows:

     Extended Term Commencement Date - November 30, 2006    $4,311.00 per month

3. PROJECT AREA. As of the Extended Term Commencement Date, Section 1(f) is
hereby amended to reduce the Project Area to an agreed 361,439 rentable square
feet and Exhibit B to the Initial Lease is replaced by Exhibit A to this First
Amendment.

4. AS IS; LANDLORD'S WORK. Tenant leases the Premises during the Extended Term
in its as-is, where-is condition and acknowledges that Landlord has not agreed
to and shall not be required to make any improvements or alterations to the
same.

5. OPTION TO RENEW. Tenant is hereby granted the right to extend the Term of the
Lease beyond the expiration date of the Extended Term for one (1) successive
period of Twelve (12) months (the "Second Extended Term"). This right to extend
may be exercised by Tenant only by giving Landlord written notice ("Notice") no
later than September 30, 2006 and no earlier than July 31, 2006. If Tenant has
defaulted in its obligations under the Lease, and failed to cure such defaults
within any applicable cure period, then Tenant's right to extend the Lease for
the Second Extended Term shall automatically terminate. Tenant's right to extend
the Lease for the Second Extended Term is personal to Tenant and may not be
exercised by any subtenant or assignee of Tenant. Tenant's extension rights
shall apply to all of the Property then leased by Tenant under this Lease. From
and after the commencement of the Second extended Term, all of the terms,
covenants, and conditions of the Lease shall continue in full force and effect
as written, except that this Section 5 shall be deleted in its entirety and Base
Monthly Rent for the Second Extended Term shall be at the then current rent
accepted by Landlord for similar space within the Project, but not less than the
Base Monthly Rent in effect for the last month of the Extended Term. Tenant
shall include with its Notice copies of Tenant's then-current financial
statement as well as financial statements from the three (3) years prior to the
current financial statement year, and shall provide Landlord with such other
financial information regarding Tenant as Landlord may require. Tenant's right
to extend the Term of this Lease for the Second Extended Term is contingent upon
Landlord approving such financial statements and information, which approval
shall not be unreasonably withheld.

<PAGE>

6. ENTIRE AGREEMENT. This First Amendment and the Amended Lease constitute the
entire agreement between Landlord and Tenant with respect to the subject matter
of this First Amendment.

7. FULL FORCE AND EFFECT. Except as specifically set forth herein, the Amended
Lease is and remains in full force and effect and binding on the parties. Tenant
confirms that Landlord is not now and has not in the past been in default under
the Lease, and Tenant has no claim against Landlord for damages or offset of any
type.

8. BROKERS. Tenant was represented in this First Amendment transaction by Bill
Neil of GVA Kidder Mathews, who shall be compensated by Landlord pursuant to a
separate written agreement. Except for the broker set forth in the preceding
sentence, each party shall indemnify, defend and hold the other party harmless
from and against all costs, expenses, attorneys' fees, liens and other liability
for commissions or other compensation claimed by any broker or agent claiming
the same by, through, or under that party.

Landlord: Teachers Insurance & Annuity
          Association of America, Inc.

By: /s/ Derek Landry
    ---------------------------------
    Derek Landry
Its: Director

Tenant: Helix BioMedix, Inc., a Delaware corporation

By: /s/ David Kirske
    ---------------------------------
    David Kirske
Its: CFO
<PAGE>

                                    EXHIBIT A
                                 (The Project)

LEGAL DESCRIPTION - PHASE II (Buildings G - H)

THAT PORTION OF THE WEST HALF OF SECTION 29 AND OF THE EAST HALF OF SECTION 30,
TOWNSHIP 27 NORTH, RANGE 5 EAST, W.M., SNOHOMISH COUNTY, WASHINGTON. DESCRIBED
AS FOLLOWS:

BEGINNING AT A POINT ON THE NORTH LINE OF THE AMENDED PLAT OF VILLAGE SQUARE,
ACCORDING TO THE PLAT RECORDED IN VOLUME 42 OF PLATS, PAGES 193 THROUGH 198,
INCLUSIVE, RECORDS OF SAID COUNTY, SAID POINT BEING NORTH 88 47' 26" EAST 627.20
FEET FROM THE NORTHWEST CORNER OF SAID PLAT;

THENCE NORTH 88 47' 26" EAST 363.00 FEET ALONG SAID NORTH LINE TO THE NORTHEAST
CORNER OF SAID PLAT;

THENCE NORTH 46 29' 12" EAST 547.38 FEET TO A POINT ON A 325 FOOT RADIUS CURVE
CONCAVE TO THE NORTHEAST, A RADIAL THROUGH SAID POINT BEARING NORTH 46 29' 12"
EAST;

THENCE NORTHWESTERLY ALONG SAID CURVE AN ARC DISTANCE OF 196.99 FEET TO A POINT
OF REVERSE CURVE WITH A 775.00 FOOT RADIUS CURVE TO THE LEFT;

THENCE NORTHERLY ALONG SAID 775.00 FOOT RADIUS CURVE AN ARC DISTANCE OF 112.88
FEET;

THENCE SOUTH 70 40' 00" WEST 272.00 FEET TO THE POINT OF CURVE OF A 450.00 FOOT
RADIUS CURVE TO THE LEFT;

THENCE WESTERLY ALONG SAID CURVE AN ARC DISTANCE OF 160.66 FEET;

THENCE SOUTH 80 52' 00" WEST 170.32 FEET;

THENCE SOUTH 68 59' 47" WEST 110.41 FEET;

THENCE SOUTH 14 04' 41" EAST 278.91 FEET;

THENCE SOUTH 17 06' 43" WEST 170.08 FEET TO THE POINT OF BEGINNING;

TOGETHER WITH AN EASEMENT FOR INGRESS, EGRESS AND UTILITIES 25.00 FEET WIDE,
BEING 12.50 FEET ON EACH SIDE OF THE FOLLOWING DESCRIBED CENTERLINE;

BEGINNING AT THE NORTHEAST CORNER OF THE ABOVE DESCRIBED PARCEL;

THENCE SOUTH 70 40' 00" WEST 272.00 FEET TO THE POINT OF A CURVE OF A 450.00
FOOT RADIUS CURVE TO THE LEFT;

THENCE WESTERLY ALONG SAID CURVE AN ARC DISTANCE OF 160.66 FEET TO THE TERMINUS
OF SAID CENTERLINE AND EASEMENT.

SITUATE IN THE COUNTY OF SNOHOMISH, STATE OF WASHINGTON.

Cross hatched area denotes Project.

                                     (MAP)

<PAGE>

STATE OF California   )
                      ) ss.
COUNTY OF Orange      )

     I certify that I know or have satisfactory evidence that Derek Landry is
the person who appeared before me, and said person acknowledged that he signed
this instrument, on oath stated that he was authorized to execute the instrument
and acknowledged it as the Director of Teachers Insurance & Annuity Association
of America, Inc. to be the free and voluntary act of such party for the uses and
purposes mentioned in the instrument.

                                        Dated: 12-6-05

                                        /s/ Carol Du Barry
                                        ----------------------------------------
                                        (Signature)

(SEAL)                                  Carol Du Barry
                                        (Print Name)

                                        Notary Public, in and for the State
                                        of CA, residing at N.B
                                        My Commission Expires 5-4-08

STATE OF Washington   )
                      ) ss.
COUNTY OF Snohomish   )

     I certify that I know or have satisfactory evidence that David Kirske is
the person who appeared before me, and said person acknowledged that he/she
signed this instrument, on oath stated that he/she was authorized to execute the
instrument and acknowledged it as the CFO of Helix BioMedix, Inc. to be the free
and voluntary act of such party for the uses and purposes mentioned in the
instrument.

                                        Dated: 12-1-05

                                        /s/ Kristen L. Mcguire
                                        ----------------------------------------
                                        (Signature)

(SEAL)                                  Kristen L. Mcguire
                                        (Print Name)

                                        Notary Public, in and for the State
                                        of Washington residing at Lake Stevens
                                        My Commission Expires 11-1-08<PAGE>
                                                                EXHIBIT 10.21(a)

                  FIRST AMENDMENT TO JOINT MARKETING AGREEMENT

        THIS FIRST AMENDMENT TO JOINT MARKETING AGREEMENT (this "AMENDMENT") is
made as of February 13, 2006 by and between Helix BioMedix, Inc., a Delaware
corporation ("HXBM"), and Body Blue Inc., a Canadian corporation ("BODY BLUE"),
and amends that certain Joint Marketing Agreement between the parties dated
effective November 2, 2004 (the "AGREEMENT"). Capitalized terms not otherwise
defined herein shall have the meanings ascribed to them in the Agreement.

        WHEREAS, the parties entered into the Agreement to provide for the
marketing of HXBM products to certain prospective customers; and

        WHEREAS, the parties wish to memorialize their agreement to share
revenues from certain other transactions which were not specifically
contemplated either by the Agreement or by that certain Referral Fee Agreement
between the parties dated September 12, 2005 (the "REFERRAL FEE AGREEMENT");

        NOW, THEREFORE, in consideration of the premises and the mutual
covenants contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties, intending
to be legally bound, do agree as follows:

1.   Revenue Share. The parties hereby agree to the following revenue share
allocations for the following corresponding transactions; provided, however,
that notwithstanding anything contained in the Agreement or this Amendment to
the contrary, both parties shall retain complete discretion as to whether or not
to engage in any transaction with any third party:

<TABLE>
<CAPTION>

      Description of Transaction                                      Amount
      --------------------------                                      ------
<S>   <C>                                             <C>

1.    Non-manufacturing agreement sourced by           Body Blue to receive ***% of HXBM
      Body Blue by which the licensing                 Net Revenue under any such agreement
      customer either sells products through
      retail channels or directly to
      consumers (e.g., ***)

2.    License Agreement sourced by Body Blue           Body Blue to receive ***% of HXBM
      with other formulators or manufacturers          Net Revenue under any such agreement.
      (e.g., companies that formulate,                 In addition, if a resulting premix
      manufacture (including outsourcing               containing an HXBM peptide is sold to
      manufacturing), and/or sell proprietary          Body Blue as a raw material for a
      mixes or turnkey products incorporating          manufacturing transaction, the premix
      HXBM's peptides, such as ***)                    cost shall be included with raw material
                                                       costs in the calculation of the profit
                                                       split as in category 3 below.

3.    Manufacturing agreements sourced by              HXBM to receive ***% of any profits from
      Body Blue involving HXBM peptides.               sales of Body Blue products under any such
                                                       agreement without regard to any Body
                                                       Blue technology that is also included, provided
                                                       that HXBM would never receive less
                                                       profit than under its standard royalty-based
                                                       licensing agreement (i.e., a target of ***%)

4.    Agreement with customer sourced by
      HXBM:

          -    HXBM refers a customer to               HXBM to receive same percentage specified in
               Body Blue for the sale of               category 1 above for referral fee (based on
               NatureBak                               total sales or royalties received by Body Blue
                                                       under any such agreement) and for any markup on
                                                       the ingredients

          -    HXBM refers a customer to               HXBM to receive ***% of profit; Body Blue
               Body Blue for a peptide-                to receive ***% of profit, provided that HXBM
               based manufacturing                     would never receive less profit than under its
               agreement                               standard royalty-based licensing agreement
                                                       (i.e., a target of ***%)

          -    Third party refers a customer for       Any commissions due to third party to be borne
               HXBM peptides to Body Blue.             by Body Blue

</TABLE>

*** CONFIDENTIAL TREATMENT REQUIRED

<PAGE>

For purposes hereof, "HXBM NET REVENUE" shall mean revenue received and
recognized by HXBM in connection with the applicable transaction or agreement,
including any license-related revenue associated with upfront, milestone or
standstill payments, net of any and all costs incurred by HXBM in manufacturing
or obtaining the product. The parties agree that HXBM Net Revenue sharing shall
only apply to non-manufacturing/license transactions (i.e., if the same kilogram
of peptide is the subject of transactions under both category 2 and category 3
above, HXBM Net Revenue shall refer only to the category 2 portion of HXBM's
revenue, and the category 3 profit split would be calculated as if the premix
were any other raw material acquired from a third party).

Any amounts payable to Body Blue hereunder shall be made by HXBM within thirty
(30) days of receipt by HXBM of the applicable Net Revenue in U.S. dollars by
wire transfer in immediately available funds to an account designated by Body
Blue. Any amounts payable to Body Blue hereunder which are not paid on the date
such payments are due shall bear interest at a rate equal to the prime rate as
published in The Wall Street Journal, Western Edition, on the first day of each
calendar month in which such payments are overdue, calculated on the number of
days such payment is delinquent, compounded monthly.

2.      Miscellaneous.  The parties further agree as follows
        -------------

        (a)    Once the parties have agreed with a customer to include a shared
               profit in the price of a peptide, the parties agree to enforce a
               minimum peptide concentration usage level with respect to such
               customer.

        (b)    The parties agree to establish different minimum concentrations
               and pricing for each market into which peptides are sold.

        (c)    The parties agree to enforce a field of use for each product.

        (d)    The parties agree to enforce unit size restrictions (e.g., no 10
               gallon units) for unit royalty agreements.

                                       2

*** CONFIDENTIAL TREATMENT REQUIRED

<PAGE>

3. Effect of Amendment. Except as specifically amended by this Amendment, all
provisions of the Agreement shall remain unchanged and in full force and effect.
Nothing contained in this Amendment shall be deemed to be an amendment of the
Referral Fee Agreement, which shall remain unchanged and in full force and
effect in its entirety. This Amendment is dated as of the date above first
written.

Helix BioMedix, Inc.                              Body Blue Inc.

____________________________________              ______________________________
By: ________________________________              By: __________________________
Its: _______________________________              Its: _________________________

                                       3

*** CONFIDENTIAL TREATMENT REQUIRED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]